Hepatitis C - Competitive Landscape, Market and Pipeline Analysis 2018

Hepatitis C - Competitive Landscape, Market and Pipeline Analysis 2018

  • Pages: 234
  • Geography: Global
  • Delivery Timeline: 24 Hours
  • Publication: Dec, 2017
  • SKU: DISR0014
  • Single User License
    (20% Off)
    $3,250.00
  • Site License
    (30% Off)
    $6,500.00
  • Global License
    (40% Off)
    $9,750.00
Request Sample

Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Address*  
Message*  
X

Request Sample Pages

Request Before Buy
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Inquire Before Buy

Send Friend
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Send to Friend

Hepatitis C - Competitive Landscape, Market and Pipeline Analysis 2017, report provides comprehensive insights about different therapeutic drugs for the treatment of Hepatitis C.

Introductionss     

Collaborations 

Technology       

Overview           

Signs and Symptoms     

Pathogenesis    

Diagnosis            

Marketed Drugs              

Vosevi: Gilead Sciences              

Product Description       

Research and Development       

Product Development Activities               

Drug Sales          

Daklinza: Bristol-Myers Squibb

Product Description       

Research and Development       

Product Development Activities               

Drug Sales          

Ximency: Bristol-Myers Squibb

Product Description       

Research and Development       

Product Development Activities               

Sunvepra: Bristol-Myers Squibb              

Product Description       

Research and Development       

Product Development Activities               

Drug Sales          

Pegasys: Roche

Product Description       

Research and Development       

Product Development Activities               

Drug Sales          

Sovaldi: Gilead Sciences             

Product Description       

Research and Development       

Product Development Activities               

Drug Sales          

Other Marketed Drug Profiles in detailed report

Clinical Pipeline Landscape       

Comparative Analysis   

Late Stage Products (Filed & Phase III) 

Comparative Analysis    

Danoprevir: Roche         

Product Description       

Research and Development       

Product Development Activities               

Glecaprevir/Pibrentasvir (G/P): AbbVie              

Product Description       

Research and Development       

Product Development Activities               

Other Drug Profiles in detailed report

Mid Stage Products (Phase II)   

Comparative Analysis   

JNJ-4178: Janssen           

Product Description       

Research and Development       

Product Development Activities               

P-1101: PharmaEssentia              

Product Description       

Research and Development       

Product Development Activities               

Other Drug Profiles in detailed report

Early Stage Products (Phase I)   

Comparative Analysis    

AVR560: AllaChem         

Product Description       

Research and Development       

Product Development Activities               

CC-31244: Cocrystal Pharma       

Product Description       

Research and Development       

Other Drug Profiles in detailed report

Pre-clinical and Discovery          

Therapeutic Assessment: Clinical Pipeline Products      

Assessment by Monotherapy Products

Assessment by Combination Products  

Assessment by Route of Administration               

Assessment by Stage and Route of Administration          

Assessment by Stage and Molecule Type            

Inactive Products            

Dormant Products          

Comparative Analysis    

Discontinued Products 

Comparative Analysis    

Drivers and Barriers       

Appendix           

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Table 1: Total Products for Hepatitis C    

Table 2: Late Stage Products (Filed and Phase III)             

Table 3: Mid Stage Products (Phase II)   

Table 4: Early Stage Products (Phase I)  

Table 5: List of Pre-clinical and Discovery Products           

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Therapy Products

Table 8: Assessment by Route of Administration              

Table 9: Assessment by Stage and Route of Administration         

Table 10: Assessment by Stage and Molecule Type         

Table 11: List of Dormant Products          

Table 12: List of Discontinued Products  

Figure 1: Course of Illness with Hepatitis C           

Figure 2: Global Epidemiology of Hepatitis C       

Figure 3: HCV Life Cycle and Pathogenesis           

Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

Other Marketed Drug Sales in detailed report (Figure 9-19).                   

Figure 20: Total Products for Hepatitis C

Figure 21: Late Stage Products (Filed and Phase III)         

Figure 22: Mid Stage Products (Phase II)               

Figure 23: Early Stage Products (Phase I)              

Figure 24: Pre-clinical and Discovery Products    

Figure 25: Assessment by Monotherapy Products           

Figure 26: Assessment by Combination Therapy Products            

Figure 27: Assessment by Route of Administration          

Figure 28: Assessment by Stage and Route of Administration     

Figure 29: Assessment by Stage and Molecule Type        

Figure 30: Dormant Products     

Figure 31: Discontinued Products             

 

Key Companies
Speak to Analyst
Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Specific Filed of Interest*  
X

Speak to Analyst

+1(919)321-6187

Related Reports

Contact Us

Phone

India: +91-11-45689769, +91-9650213330
Outside India: +1(919)321-6187

Email

info@delveinsight.com

Address

New Delhi-110075, India

Latest Tweets

Copyright © 2018 Delveinsight.